NCT06851221Completed
Β3-adrenoreceptor As Prognostic Marker in Neuroblastoma and Ewing Sarcoma
Source: ClinicalTrials.gov · Last updated 28 Feb 2025
Brief summary (registry, in English)
This study on biological samples of patients affected by neuroblastoma and Ewing sarcoma aims at validating the beta3-adrenoreceptor as prognostic biomarker.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 95 (actual)
- First submitted
- 21 Feb 2025
- Start date
- 5 Aug 2020
- Primary completion date
- 5 Mar 2024
- Lead sponsor
- Meyer Children's Hospital IRCCS
- Diseases
- Neuroblastoma, Childhood cancers, Sarcoma
- NCT number
- NCT06851221
What you commit to
- Study type: Interventional
- Participants enrolled: 95
- From 5 Aug 2020 to the primary completion date, 5 Mar 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- sieropositivity
Who the study is looking for
- diagnosis of Ewing sarcoma or neuroblastoma
Age in the registry: 0 years to 18 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Laboratorio traslazionale in oncoematologia Coordinator of this site? Confirm its status | Florence | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.